Karyopharm pauses endometrial cancer program update; in talks with FDA about Phase 3 trial

Karyopharm Therapeutics Inc.

Company in discussions with FDA regarding evolving treatment landscape for endometrial cancer and its impact on Phase 3 XPORT-EC-042 trial.
Karyopharm will not discuss endometrial cancer program at Piper Sandler conference on Dec 3, 2024.
Company intends to provide update on endometrial cancer program after FDA discussion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.